CM Life Sciences II To Combine With Proteomics SomaLogic In Latest SPAC Deal
Executive Summary
The SPAC deal between CM Life Sciences II and SomaLogic is valued at $1.25bn.
You may also be interested in...
Surgical Robotics Company Vicarious Surgical To Merge With D8 SPAC In $1.1Bn Deal
Vicarious Surgical, whose medical robot received US FDA breakthrough designation, announced it will merge with D8 Holdings Corp. The deal is expected to garner up to $460m.
Finance Watch: Investors Launch New SPACs After Initial Deals
EcoR1 and Casdin/Corvex took their second and third special purpose acquisition corporations public. Also, Ionis sold notes to buy back older notes and fund operations as it cut 70% of Akcea’s staff. In venture capital, ValenzaBio raised $70m and RA boosted Metagenomi’s series A to $75m.
Diagnostic Company LumiraDX Goes Public In $5Bn SPAC Merger
LumiraDX secured $400m in new debt financing and will use all proceeds to fund growth.